Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-04-03
2007-04-03
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S143100, C424S141100, C424S133100, C424S135100, C514S002600, C530S350000, C530S388220, C530S388100, C530S387100, C530S387300, C530S387900, C536S023500
Reexamination Certificate
active
10264634
ABSTRACT:
Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.
REFERENCES:
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5155027 (1992-10-01), Sledziewski et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5567584 (1996-10-01), Sledziewski et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5750375 (1998-05-01), Sledziewski et al.
patent: 5840844 (1998-11-01), Lasky et al.
patent: 5843725 (1998-12-01), Sledziewski et al.
patent: 6018026 (2000-01-01), Sledziewski et al.
patent: 6057128 (2000-05-01), Donaldson et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6291212 (2001-09-01), Sledziewski et al.
patent: 6291646 (2001-09-01), Sledziewski et al.
patent: 6300099 (2001-10-01), Sledziewski et al.
patent: 6307024 (2001-10-01), Novak et al.
patent: 6323323 (2001-11-01), Sledziewski et al.
patent: 6406697 (2002-06-01), Capon et al.
patent: 6576744 (2003-06-01), Presnell et al.
patent: 6692924 (2004-02-01), Presnell et al.
patent: 2001/0025022 (2001-09-01), Kikly et al.
patent: 2002/0090680 (2002-07-01), Hodge
patent: 2002/0128446 (2002-09-01), Novak et al.
patent: 2002/0137677 (2002-09-01), Sprecher et al.
patent: 2002/0160451 (2002-10-01), Masiakowski et al.
patent: 2003/0134390 (2003-07-01), Presnell et al.
patent: 2003/0148447 (2003-08-01), Presnell et al.
patent: 0 812 913 (1997-12-01), None
patent: 1 088 831 (2001-04-01), None
patent: WO 96/04388 (1996-02-01), None
patent: WO 97/20926 (1997-06-01), None
patent: WO 97/31946 (1997-09-01), None
patent: WO 97/33913 (1997-09-01), None
patent: WO 97/47741 (1997-12-01), None
patent: WO 97/47742 (1997-12-01), None
patent: WO 98/10638 (1998-03-01), None
patent: WO 98/11225 (1998-03-01), None
patent: WO 98/31811 (1998-07-01), None
patent: WO 99/47675 (1999-09-01), None
patent: WO 99/67290 (1999-12-01), None
patent: WO 00/08152 (2000-02-01), None
patent: WO 00/17235 (2000-03-01), None
patent: WO 00/27882 (2000-05-01), None
patent: WO 00/53761 (2000-09-01), None
patent: WO 00/69880 (2000-11-01), None
patent: WO 01/36467 (2001-05-01), None
patent: WO 01/46261 (2001-06-01), None
patent: WO 01/77171 (2001-10-01), None
D'Andrea et al., “Expression cloning of the murine erythropoietin receptor,”Cell, 57:277-285 (1989).
Hatakeyama et al., “Interleukin-2 receptor beta chain gene: Generation of three receptor forms by cloned human alpha and beta chain cDNA's,”Science, 244:551-556 (1989).
GenBank Accession No. M26062 Human interleukin 2 receptor beta chain (p70-75) mRNA, complete cds.
Yan et al., “Two-Amino Acid Molecular Switch in an Epithelial Morphogen That Regulates Binding to Two Distinct Receptors,”Science, 290:523-527 (2000).
Parrish-Novak, et al., “Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function,”Nature, 408:57-63 (2000).
Ozaki, et al., “Cloning of a type I cytokine receptor most related to the IL-2 receptor β chain,”Proc. Natl. Acad. Sci. USA, 97(21):11439-11444 (2000).
EMBL Database Accession No. AC002302 (Jun. 26, 1997).
Bazan, “Structural design and molecular evolution of a cytokine receptor superfamily”Proc. Natl. Acad. Sci. USA, 87:6934-6938, (1990).
Dusanter-Fourt, et al., “Tranduction du signal par les recepteurs de cytokines”Medecine/Sciences 10:825-835. English Abstract.
O'Dowd, et al., “Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes,”Gene 187(1):75-81, (1997).
International Search Report for PCT/US 99/05854. Mailed on Aug. 17, 1999.
Database EMBL. ID HS795114, Accession No. R52795, May 25, 1995.
Caput, D., et al., “Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor a chain,”The Journal of Biological Chemistry, 271(28):16921-16926, (1996).
Vita, N., et al., “Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types,”Journal of Biological Chemistry, 270(8):3512-3517, (1995).
Biró, et al., “The effects of wsews pentapeptide and wsews-specific monoclonal antibodies on constitutive and 11-6 induced acute phase,”Immunology Letters, 46:183-187, (1995).
Zhang, et al., “Identification, purification, and characterization of a soluble interleukin (IL)-13 binding protein,”Journal of Biological Chemistry, 272(14):9474-9480, (1997).
Debinski, W., et al., “A novel chimeric protein composed of interleukin-13 and pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin-13 and interleukin-4,”Journal of Biological Chemistry, 270(28):16775-16780, (1995).
Page, L.A., et al., “An antiproliferative bioassay for interleukin-4,”Journal of Immunological Methods, 189(1):129-135, (1996).
Lai Chun-Fai, et al., “STAT3 and STAT5B are targets of two different signal pathways activated by hematopoietin receptors and control transcription via separate cytokine response elements,”Journal of Biological Chemistry, 270(40):23254-23257, (1995).
Database EMBL, Accession No. AF279436, Jul. 18, 2000.
Database EMBL, Accession No. AB049137, Sep. 23, 2000.
Bazan “Structural design and molecular evolution of a cytokine receptor superfamily,” Proc. Natl. Acad. Sci. USA 87:6934-38 (1990).
Imler et al. “Identification of three adjacent amino acids of interleukin-2 receptor β chain which control the affinity and the specificity of the interaction with interleukin-2,” EMBO J. 11:2047-53 (1992).
LaRosa et al. “Amino Terminus of the Interleukin-8 Receptor Is a Major Determinant of Receptor Subtype Specificity,” J. Biol. Chem. 267:25402-06 (1992).
Schimmenti et al. “Localization of an essential ligand binding determinant of the human erythropoietin receptor to a domin N-terminal to the WSXWS motif: implications for soluble receptor function,” Exp. Hematol. 23:1341-46 (1995).
Mulhern et al. “The Solution Structure of the Cytokine-binding Domain of the Common β-Chain of the Receptors for Granulocyte-Macrophage Colony-stimulating Factor, Interleukin-3 and Interleukin-5,” J. Mol. Biol. 297:989-1001 (2000).
Woodcock et al. “Three residues in the common β chain of the human GM-CSF, IL-3 and IL-5 receptors are essential for GM-CSF and IL-5 but not IL-3 high affinity binding and interact with Glu21 of GM-CSF,” EMBO J. 13:5176-85 (1994).
Carreno Beatriz
Carter Laura
Collins Mary
Donaldson Debra D.
Dunussi Kyri
Fitzpatrick ,Cella, Harper & Scinto
Genetics Institute LLC
O'Hara Eileen B.
LandOfFree
Methods and compositions for modulating interleukin-21... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for modulating interleukin-21..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating interleukin-21... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3753940